Replies to post #148199 on Biotech Values

[mcbio]

Not really - they are going after an oncology indication, which is quite different from a stem cell transplant indication. Also plerixafor is a small molecule drug and this is a peptide.

Yeah, fair enough. I think I should have worded that a little different. I think it's good to see the company with a drug already approved and on the market with this MoA, Genzyme, sees the utility in further expanding the testing of this kind of drug in oncology. It gives me more confidence in BLRX's chances than had there been no drug with this MoA on the market at all.

Is a small molecule more preferable than a peptide in this type of setting?

Here's an interesting article I found from March of this year showing the benefits of plerixafor in AML: http://www.medicalnewstoday.com/articles/243309.php .